Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease
- PMID: 12944403
- DOI: 10.1074/jbc.M301874200
Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease
Abstract
Cerebral amyloid angiopathy (CAA) due to beta-amyloid (Abeta) is one of the specific pathological features of familial Alzheimer's disease. Abeta mainly consisting of 40- and 42-mer peptides (Abeta40 and Abeta42) exhibits neurotoxicity and aggregative abilities. All of the variants of Abeta40 and Abeta42 found in CAA were synthesized in a highly pure form and examined for neurotoxicity in PC12 cells and aggregative ability. All of the Abeta40 mutants at positions 22 and 23 showed stronger neurotoxicity than wild-type Abeta40. Similar tendency was observed for Abeta42 mutants at positions 22 and 23 whose neurotoxicity was 50-200 times stronger than that of the corresponding Abeta40 mutants, suggesting that these Abeta42 mutants are mainly involved in the pathogenesis of CAA. Although the aggregation of E22G-Abeta42 and D23N-Abeta42 was similar to that of wild-type Abeta42, E22Q-Abeta42 and E22K-Abeta42 aggregated extensively, supporting the clinical evidence that Dutch and Italian patients are diagnosed as hereditary cerebral hemorrhage with amyloidosis. In contrast, A21G mutation needs alternative explanation with the exception of physicochemical properties of Abeta mutants. Attenuated total reflection-Fourier transform infrared spectroscopy spectra suggested that beta-sheet content of the Abeta mutants correlates with their aggregation. However, beta-turn is also a critical secondary structure because residues at positions 22 and 23 that preferably form two-residue beta-turn significantly enhanced the aggregative ability.
Similar articles
-
Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23.Biochem Biophys Res Commun. 2002 May 31;294(1):5-10. doi: 10.1016/S0006-291X(02)00430-8. Biochem Biophys Res Commun. 2002. PMID: 12054732
-
Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement.J Biol Chem. 2004 Dec 10;279(50):52781-8. doi: 10.1074/jbc.M406262200. Epub 2004 Sep 30. J Biol Chem. 2004. PMID: 15459202
-
Structural heterogeneity in familial Alzheimer's disease mutants of amyloid-beta peptides.Mol Biosyst. 2013 May;9(5):997-1003. doi: 10.1039/c2mb25457c. Mol Biosyst. 2013. PMID: 23358498
-
The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease.Geriatr Gerontol Int. 2010 Jul;10 Suppl 1:S169-79. doi: 10.1111/j.1447-0594.2010.00598.x. Geriatr Gerontol Int. 2010. PMID: 20590832 Review.
-
Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor.Ann N Y Acad Sci. 2002 Nov;977:258-65. doi: 10.1111/j.1749-6632.2002.tb04824.x. Ann N Y Acad Sci. 2002. PMID: 12480759 Review.
Cited by
-
Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation.Biophys J. 2015 Feb 3;108(3):738-47. doi: 10.1016/j.bpj.2014.12.013. Biophys J. 2015. PMID: 25650940 Free PMC article.
-
Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer.Biophys J. 2012 Jan 18;102(2):315-24. doi: 10.1016/j.bpj.2011.12.002. Biophys J. 2012. PMID: 22339868 Free PMC article.
-
Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A beta 42-amyloid oligomers.J Mol Model. 2010 May;16(5):1011-20. doi: 10.1007/s00894-009-0611-1. Epub 2009 Nov 12. J Mol Model. 2010. PMID: 19908073
-
Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation.Biochem J. 2013 Dec 15;456(3):347-60. doi: 10.1042/BJ20130652. Biochem J. 2013. PMID: 24028142 Free PMC article.
-
Evaluation of Amyloid Polypeptide Aggregation Inhibition and Disaggregation Activity of A-Type Procyanidins.Pharmaceuticals (Basel). 2021 Oct 31;14(11):1118. doi: 10.3390/ph14111118. Pharmaceuticals (Basel). 2021. PMID: 34832900 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous